Investor Presentaiton slide image

Investor Presentaiton

Immunology LPA₁ Sotyktu CD19 NEX T Potential transformative treatment option for patients with certain severe immunologic diseases BMS-986353 expresses the same CD19 specific CAR construct as best-in-class Breyanzi 1,2 Anti-CD19 Targeting Domain 1,2 Extracellular single-chain variable fragment to recognize CD19 CD28 Hinge/Transmembrane Domain³ 4-1BB Costimulatory Domain 1,2 Stimulates CD8+ central memory T-cell generation and favors CAR T-cell persistence4 CD3-Activation Domain 1,2 Breyanzi achieves rapid and complete B-cell depletion in patients with B-cell malignancies NEXT: Next generation technology manufacturing platform balances speed and robustness Faster turnaround time Optimized cell expansion time Increased productivity • Leverages a closed and automated manufacturing platform leads to increased yield and lowered cost Innovative technologies Proprietary harvest technology improves purity CD19 NEX T: Differentiated safety profile of Breyanzi with an enhanced manufacturing process 1. Makita S, et al. Drugs Context. 2019;8:212567. 2. Teoh J, et al. Blood. 2019;134:593. 3. Jayaraman J, et al. EBioMedicine. 2020;58:102931. 4. Weinkove R, et al. Clin Ill Bristol Myers Squibb Transl Immunol. 2019:8;e1049. Not for Product Promotional Use 69
View entire presentation